Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Cell ProliferationOpen Access

PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMiao WangYCYing CaoCRChengcheng Ren

Discussion

Loading...

Member takes

Overview

Observational analysis shows increased EGFR and PTRF in drug-resistant melanoma, suggesting new targets for therapy.

Key Points

  • Melanoma cells with increased PTRF show heightened drug resistance, reducing sensitivity to BRAF inhibitors.
  • Knockdown of PTRF decreases EGFR levels significantly, restoring sensitivity to BRAFi in resistant melanoma cells.
  • Ectopic expression of PTRF in parental cells leads to acquisition of resistance against BRAF inhibitors, indicating its role.
  • This research highlights the potential for targeting the PTRF-EGFR pathway to reverse drug resistance in melanoma.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c23ed7b210217d64794a0chttps://doi.org/10.1111/cpr.70086
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review2025 · 18 citations
  2. 2Rapid activation of ARF6 after RAF inhibition augments BRAFV600E and promotes therapy resistance2025
  3. 3Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells2025
  4. 4Phenotype switching in highly invasive resistant to vemurafenib and cobimetinib melanoma cells2025 · 5 citations
  5. 5NR2F1 and mTORC1 provide the bridge between melanoma dormancy and therapeutic resistance2025